ISAL 2019 | Risk-adapted therapy of AML

Name: Risk-adapted therapy of AML
Uploaded: 2019-03-01T15:42:56.000Z
Duration: 1 min 29 s
Description: Christoph Röllig, MD, MSc, of Dresden University of Technology, Dresden, Germany, discusses the risk-adapted therapy of acute myeloid leukemia (AML), highlighting the rationale behind combination therapy in specific subgroups. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Christoph Röllig • 1 Mar 2019

ISAL 2019

Acute Myeloid Leukemia Leukemia

Christoph Röllig, MD, MSc, of Dresden University of Technology, Dresden, Germany, discusses the risk-adapted therapy of acute myeloid leukemia (AML), highlighting the rationale behind combination therapy in specific subgroups. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.